uniQure appoints Basilea’s chief commercial officer

pharmafile | December 6, 2012 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing Basilea, uniQure 

Dutch human gene therapy firm uniQure has appointed Hans Christian Rohde as chief commercial officer.

Rohde joins uniQure from Basilea Pharmaceutica, where from 2007 he was chief commercial officer and member of the company’s executive management committee with responsibility for global commercial operations, marketing, supply chain, medical affairs, pricing and market access.

“We are very pleased with Hans Christian’s appointment,” said Jörn Aldag, chief executive of uniQure. “Hans Christian’s experience and successful track-record in major biotechnology companies such as Basilea, Merck-Serono and Biogen Idec provide us with the necessary leadership qualities to successfully commercialise Glybera.”

Rohde has almost 25 years’ experience in commercial roles at leading biotechnology and pharmaceutical companies. Prior to Basilea he was corporate vice president, head of Global Therapeutic Areas Reproductive Health and Endocrinology at Merck-Serono from 2003 until 2007.

Prior to this he was responsible for international marketing and global market development at Biogen Idec. From 1992 until 2000, Rohde held positions of increasing commercial responsibility at Novo Nordisk. He started his career at Laboratoires Syntex.

Related Content

uniQure announces sale of royalty interest in Hemgenix for up to $400m

uniQure has announced that it has entered a definitive agreement to sell a portion of …

BMS image

BMS enters gene therapy development deal

Bristol-Myers Squibb (BMS) has signed a multi-million dollar agreement with Amsterdam-based gene therapy firm uniQure …

FDA approves new anti-fungal treatment

The FDA has given the OK to Astellas and Basilea for their new treatment in …

Latest content